製品番号: HY-N3009

Secoxyloganin

(別名: セコキシロガニン)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Secoxyloganin is an orally effective iridoid derivative. Secoxyloganin can be isolated from the flower buds of L. japonica. Secoxyloganin induces Apoptosis by inhibiting the expression of Bcl-2. Secoxyloganin potently inhibits the proliferation of breast cancer cells, while exerting weak activity against normal mammary epithelial cells. Secoxyloganin inhibits the decrease in tail vein blood flow associated with allergic reactions.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.33%
CAS 番号: 58822-47-2
分子式: C₁₇H₂₄O₁₁
分子量:404.37

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Secoxyloganin 構造式

CAS 番号: 58822-47-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

Bcl-2

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

体外実験

Secoxyloganin (0.37-96 µM; 24 h) potently inhibits the proliferation of breast cancer MDA-MB-231 cells with an IC₅₀ of 6.5 µM, while it shows weak activity against normal fR2 mammary epithelial cells with an IC₅₀ of 38 µM^[1].
Secoxyloganin (6-24 µM) induces concentration-dependent DNA damage in breast cancer MDA-MB-231 cells^[1].
Secoxyloganin (6-24 µM; 24 h) induces concentration-dependent apoptosis in breast cancer MDA-MB-231 cells^[1].
Secoxyloganin (6-24 µM; 24 h) regulates the expression of apoptosis-related proteins in human breast cancer MDA-MB-231 cells, upregulating Bax and decreasing Bcl-2^[1].
Secoxyloganin (6-24 µM) induces G₀/G₁ cell cycle arrest in breast cancer MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

human breast cancer MDA-MB-231 cells
Concentration:

6-24 µM
Incubation Time:

24 h
Result:

Induced a concentration-dependent increase in apoptosis in MDA-MB-231 cells, with increased intensities of early apoptotic yellow-green fluorescence and late apoptotic orange-red fluorescence at higher concentrations.
Increased the percentage of apoptotic MDA-MB-231 cells from 3.7% in control to 21.8% at 6 µM, 30.3% at 12 µM, and 40.2% at 24 µM.

Cell Cycle Analysis^[1]

Cell Line:

human breast cancer MDA-MB-231 cells
Concentration:

6-24 µM
Incubation Time:

Certain time
Result:

Increased the proportion of MDA-MB-231 cells in the G₀/G₁ phase from 32.76% in control to 43.61% at 6 µM, 69.79% at 12 µM, and 77.50% at 24 µM, indicating G₀/G₁ cell cycle arrest.

体内実験

Secoxyloganin (10 mg/kg; p.o.; administered on days 0, 3, 6, and 9) significantly inhibits the decrease in tail vein blood flow in lysozyme-sensitized mice without affecting platelet aggregation^[2].\n

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ddY mice (male, 5 weeks old, SPF grade, sensitized intraperitoneally with HEL in complete Freund’s adjuvant)^[2]
Dosage:

10 mg/kg
Administration:

p.o.; 4 doses on days 0, 3, 6, 9
Result:

Significantly inhibited the HEL-induced decrease in tail vein BF compared to the HEL-sensitized control group after day 7 of sensitization, with BF remaining near 100% of normal levels through day 9 (control BF dropped to ~70% of normal).
Showed no inhibitory effect on ADP-induced whole blood platelet aggregation in HEL-sensitized mice on day 9.

化学情報

CAS 番号 58822-47-2
性状 Solid
分子量 404.37
分子式 C₁₇H₂₄O₁₁
Color White to light yellow
SMILES

C=C[C@@H]1[C@@H](C(C(OC)=O)=CO[C@@]1([H])O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)CC(O)=O
別名

セコキシロガニン
Structure Classification
- Terpenoids
- Iridoids
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Phytomedicine

A novel mechanism of Reduning injection in sepsis treatment: Targeting inflammatory kinases TBK1 and IKKβ. [Abstract]

2026 Feb:151:157776. PMID: 41512388

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (247.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4730 mL

12.3649 mL

24.7298 mL

5 mM

0.4946 mL

2.4730 mL

4.9460 mL

10 mM

0.2473 mL

1.2365 mL

2.4730 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ma J, et al. Secoxyloganin inhibits growth of breast cancer MDA-MB-231 cells via induction of apoptosis and cell cycle arrest[J]. All Life, 2024, 17(1): 2408433.

[2]. Oku H, et al. Allergy-preventive effects of chlorogenic acid and iridoid derivatives from flower buds of Lonicera japonica. Biol Pharm Bull. 2011;34(8):1330-1333. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4730 mL	12.3649 mL	24.7298 mL	61.8246 mL
	5 mM	0.4946 mL	2.4730 mL	4.9460 mL	12.3649 mL
	10 mM	0.2473 mL	1.2365 mL	2.4730 mL	6.1825 mL
	15 mM	0.1649 mL	0.8243 mL	1.6487 mL	4.1216 mL
	20 mM	0.1236 mL	0.6182 mL	1.2365 mL	3.0912 mL
	25 mM	0.0989 mL	0.4946 mL	0.9892 mL	2.4730 mL
	30 mM	0.0824 mL	0.4122 mL	0.8243 mL	2.0608 mL
	40 mM	0.0618 mL	0.3091 mL	0.6182 mL	1.5456 mL
	50 mM	0.0495 mL	0.2473 mL	0.4946 mL	1.2365 mL
	60 mM	0.0412 mL	0.2061 mL	0.4122 mL	1.0304 mL
	80 mM	0.0309 mL	0.1546 mL	0.3091 mL	0.7728 mL
	100 mM	0.0247 mL	0.1236 mL	0.2473 mL	0.6182 mL

Keywords

Secoxyloganin

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Secoxyloganin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Glycoside Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Heterocyclic Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Secoxyloganin

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Secoxyloganin 関連分類

HY-N3009 関連分類